Oren Livnat, an analyst from H.C. Wainwright, maintained the Buy rating on Xeris Pharmaceuticals (XERS – Research Report). The associated price target is $8.00.
Oren Livnat’s rating is based on several compelling factors that highlight Xeris Pharmaceuticals’ potential for growth and financial stability. Firstly, the company’s guidance for 2025 revenue, which ranges from $255 to $275 million, exceeded expectations by 11% and demonstrated a significant year-over-year increase. This strong guidance provides a clear path to achieving cash flow breakeven, which is a critical milestone for the company.
Moreover, Xeris has shown impressive operating leverage, with operating expenses expected to rise only modestly, suggesting improved profitability. The company’s innovative product pipeline, particularly the XP-8121 autoinjector, presents a transformative opportunity that could capture a significant market share. Additionally, Xeris’s existing products, Recorlev and Gvoke, have long-term intellectual property protection, ensuring sustained revenue growth. These factors, combined with the company’s undervaluation relative to its peers, justify the Buy rating and the increased price target of $8.
Livnat covers the Healthcare sector, focusing on stocks such as Avadel Pharmaceuticals, Pacira Pharmaceuticals, and Cara Therapeutics. According to TipRanks, Livnat has an average return of 0.0% and a 41.94% success rate on recommended stocks.
Questions or Comments about the article? Write to editor@tipranks.com